Korro Bio, Inc. selects KRRO-111 after preclinical success in repairing AAT protein

Korro Bio, Inc. selects KRRO-111 after preclinical success in repairing AAT protein
Korro Bio, Inc. advances AATD therapy

Korro Bio, Inc. has designated KRRO-111 as its development candidate for the potential treatment of Alpha-1 Antitrypsin Deficiency (AATD).

In preclinical studies, KRRO-111 demonstrated greater than 90 percent RNA editing of SERPINA1 transcripts, resulting in approximately 90 percent restoration of functional AAT protein. This progress positions KRRO-111 as a promising early-stage asset in the pursuit of therapies targeting genetic defects in AATD. Further studies will determine its viability for advancement into clinical development.

Korro Bio has previously reported progress on its RNA editing therapies for genetic conditions. In May, the company announced new advancements for KRRO-121, its therapy targeting hyperammonemia, at ASGCT2026. The firm continues to expand its early-stage pipeline in liver and metabolic diseases.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.